Biotronik announced the first enrollments in the BIO|GUARD-MI1 study. The study will investigate whether the early detection of cardiac arrhythmias offered by BioMonitor, and subsequent treatments, reduce the likelihood of major adverse cardiovascular events (MACE). The study will, for the first time ever, examine patients with relatively preserved left ventricular ejection fraction (LVEF > 35 percent), who have experienced acute myocardial infarction (AMI).

Boston Scientific has become a significant shareholder and will become the exclusive worldwide sales and marketing representative for Preventice Solutions for cardiology-related diagnostic and monitoring offerings.

The Technology Partnership (TTP), a U.K.-based research and product development company, has made major advances in the use of elastography, a medical imaging technique that maps elastic properties of soft tissue to provide vital diagnostic information during surgery. The new breakthrough could be used for surgical processes such as treating abnormal heart rhythms caused by atrial fibrillation, killing or removing cancerous or damaged tissue, or simply navigating around the body during an operation.